169 related articles for article (PubMed ID: 37553313)
1. FMO1 Promotes Nonalcoholic Fatty Liver Disease Progression by Regulating PPARα Activation and Inducing Ferroptosis.
Zou L; Shi Q; Li Y; Yuan Z; Peng L; Lu J; Zhu H; Ma J
Discov Med; 2023 Aug; 35(177):612-622. PubMed ID: 37553313
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia exacerbates nonalcoholic fatty liver disease via the HIF-2α/PPARα pathway.
Chen J; Chen J; Fu H; Li Y; Wang L; Luo S; Lu H
Am J Physiol Endocrinol Metab; 2019 Oct; 317(4):E710-E722. PubMed ID: 31430204
[TBL] [Abstract][Full Text] [Related]
3. Pdcd4 promotes lipid deposition by attenuating PPARα-mediated fatty acid oxidation in hepatocytes.
Du X; Osoro EK; Chen Q; Yan X; Gao D; Wu L; Ren J; Feng L; Wu N; Lu K; Yang X; Zhong B; Han Y; Zhang F; Li D; Lan X; Lu S
Mol Cell Endocrinol; 2022 Apr; 545():111562. PubMed ID: 35051553
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of miR-181a impairs lipid metabolism by targeting PPARα expression in nonalcoholic fatty liver disease.
Huang R; Duan X; Liu X; Cao H; Wang Y; Fan J; Wang B
Biochem Biophys Res Commun; 2019 Jan; 508(4):1252-1258. PubMed ID: 30558790
[TBL] [Abstract][Full Text] [Related]
5. Fat mass and obesity-associated protein promotes liver steatosis by targeting PPARα.
Wei X; Zhang J; Tang M; Wang X; Fan N; Peng Y
Lipids Health Dis; 2022 Mar; 21(1):29. PubMed ID: 35282837
[TBL] [Abstract][Full Text] [Related]
6. PPARα is one of the key targets for dendrobine to improve hepatic steatosis in NAFLD.
Xu Y; Wang M; Luo Y; Liu H; Ling H; He Y; Lu Y
J Ethnopharmacol; 2024 Apr; 323():117684. PubMed ID: 38171466
[TBL] [Abstract][Full Text] [Related]
7. A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPARα) and farnesoid X receptor (FXR).
Zhou S; You H; Qiu S; Yu D; Bai Y; He J; Cao H; Che Q; Guo J; Su Z
Biomed Pharmacother; 2022 Oct; 154():113577. PubMed ID: 35988420
[TBL] [Abstract][Full Text] [Related]
8. Chlorogenic Acid Attenuates Hepatic Steatosis by Suppressing ZFP30.
Ding H; Ge K; Fan C; Liu D; Wu C; Li R; Yan FJ
J Agric Food Chem; 2024 Jan; 72(1):245-258. PubMed ID: 38148374
[TBL] [Abstract][Full Text] [Related]
9. Silybin alleviates hepatic lipid accumulation in methionine-choline deficient diet-induced nonalcoholic fatty liver disease in mice via peroxisome proliferator-activated receptor α.
Cui S; Pan XJ; Ge CL; Guo YT; Zhang PF; Yan TT; Zhou JY; He QX; Cheng LH; Wang GJ; Hao HP; Wang H
Chin J Nat Med; 2021 Jun; 19(6):401-411. PubMed ID: 34092291
[TBL] [Abstract][Full Text] [Related]
10. Resveratrol protects against nonalcoholic fatty liver disease by improving lipid metabolism and redox homeostasis via the PPARα pathway.
Huang Y; Lang H; Chen K; Zhang Y; Gao Y; Ran L; Yi L; Mi M; Zhang Q
Appl Physiol Nutr Metab; 2020 Mar; 45(3):227-239. PubMed ID: 31173696
[TBL] [Abstract][Full Text] [Related]
11. Hepatic
Lee YH; Jang HJ; Kim S; Choi SS; Khim KW; Eom HJ; Hyun J; Shin KJ; Chae YC; Kim H; Park J; Park NH; Woo CY; Hong CH; Koh EH; Nam D; Choi JH
Elife; 2021 Dec; 10():. PubMed ID: 34964438
[TBL] [Abstract][Full Text] [Related]
12. Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD.
Montagner A; Polizzi A; Fouché E; Ducheix S; Lippi Y; Lasserre F; Barquissau V; Régnier M; Lukowicz C; Benhamed F; Iroz A; Bertrand-Michel J; Al Saati T; Cano P; Mselli-Lakhal L; Mithieux G; Rajas F; Lagarrigue S; Pineau T; Loiseau N; Postic C; Langin D; Wahli W; Guillou H
Gut; 2016 Jul; 65(7):1202-14. PubMed ID: 26838599
[TBL] [Abstract][Full Text] [Related]
13. LB100 ameliorates nonalcoholic fatty liver disease
Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
[TBL] [Abstract][Full Text] [Related]
14. Water Extract of Dolichos lablab Attenuates Hepatic Lipid Accumulation in a Cellular Nonalcoholic Fatty Liver Disease Model.
Im AR; Kim YH; Lee HW; Song KH
J Med Food; 2016 May; 19(5):495-503. PubMed ID: 27152979
[TBL] [Abstract][Full Text] [Related]
15. CRISPR-mediated BMP9 ablation promotes liver steatosis via the down-regulation of PPARα expression.
Yang Z; Li P; Shang Q; Wang Y; He J; Ge S; Jia R; Fan X
Sci Adv; 2020 Nov; 6(48):. PubMed ID: 33246954
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of hepatic CLOCK by PPARα is involved in inhibition of NAFLD.
Luo J; Yan Z; Dai M; Xu L; Zhang H; Xi Y; Yang J; Liu A
J Mol Med (Berl); 2023 Feb; 101(1-2):139-149. PubMed ID: 36527474
[TBL] [Abstract][Full Text] [Related]
17. PARP1-mediated PPARα poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease.
Huang K; Du M; Tan X; Yang L; Li X; Jiang Y; Wang C; Zhang F; Zhu F; Cheng M; Yang Q; Yu L; Wang L; Huang D; Huang K
J Hepatol; 2017 May; 66(5):962-977. PubMed ID: 27979751
[TBL] [Abstract][Full Text] [Related]
18. PRDX6 Promotes Fatty Acid Oxidation
Shen W; Yang L; Yang Y; Wang P; Tao X; Shen Y; Wang S; Shen Y
Antioxid Redox Signal; 2023 Jun; 38(16-18):1184-1200. PubMed ID: 36401357
[No Abstract] [Full Text] [Related]
19. Mesencephalic astrocyte-derived neurotrophic factor ameliorates steatosis in HepG2 cells by regulating hepatic lipid metabolism.
He M; Wang C; Long XH; Peng JJ; Liu DF; Yang GY; Jensen MD; Zhang LL
World J Gastroenterol; 2020 Mar; 26(10):1029-1041. PubMed ID: 32205994
[TBL] [Abstract][Full Text] [Related]
20. Gentiopicroside Ameliorates Oxidative Stress and Lipid Accumulation through Nuclear Factor Erythroid 2-Related Factor 2 Activation.
Jin M; Feng H; Wang Y; Yan S; Shen B; Li Z; Qin H; Wang Q; Li J; Liu G
Oxid Med Cell Longev; 2020; 2020():2940746. PubMed ID: 32655764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]